Letters to Officials
CCAGW Urges House of Representatives to Support Amendments to H.R. 8070
Members of Congress should support amendments that would increase transparency and financial responsibility.
Testimony of Thomas A Schatz House Energy and Commerce Subcommittee on Oversight and Investigations
Tom Schatz, President, CCAGW Submits Testimony on "Oversight of 340B Drug Pricing Program."
CCAGW Joins Coalition Supporting Reforms to the Sugar Program
The modest reforms included in the House farm bill are a meaningful first step to reforming the sugar program.
CCAGW Urges Senate Judiciary Committee to Support IP Rights in Pharmaceutical Drug Industry
Weakening IP rights will hinder the future research and development needed to create new cures and technologies.
CCAGW Leads Coalition Supporting H.R. 8051, the Earmark Elimination Act
H.R. 8051 would create a permanent ban on earmarks in the House of Representatives.
CCAGW Urges Senate Homeland Security and Government Affairs Committee to Support S. 2871
S. 2871 would make federal agencies more secure and efficient while reducing costs and duplication.
CCAGW Urges House Oversight Committee to Support H.R. 262
The ALERT Act would bring more accountability and transparency to the regulatory process.
CAGW Joins Coalition Opposing Cuts to Medicare Advantage Program
Medicare Advantage is provided through private plans rather than government-run plans and allows private companies to compete.
CAGW Joins Coalition Opposing Cuts to Medicare Advantage Program
Medicare Advantage is provided through private plans rather than government-run plans and allows private companies to compete.
CCAGW Urges House Oversight Committee to Support H.R. 262
The ALERT Act would bring more accountability and transparency to the regulatory process.
CCAGW Urges House Oversight Committee to Oppose H.R. 6283
H.R. 6283 would impose unnecessary and harmful regulations on PBMs that will lead to higher prices and fewer options.
CCAGW Urges West Virginia Legislators to Oppose Senate Bill 325
SB 325 would make changes to the federal 340B drug discount program.
